Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Hemispherx BioPharma, Inc    

News SummaryMost relevantAll newsSector newsTweets 

Hemispherx BioPharma, Inc : Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
12/28/2012 | 06:35pm EDT

WAYNE, Pa., Dec. 28, 2012 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/heb) announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (NYSE MKT: HEB) common stock during the period between March 19, 2012 and December 17, 2012, inclusive (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at [email protected] or visit: www.rmclasslaw.com/cases/heb.

Hemispherx is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen(R) ("Ampligen"), is undergoing clinical trials for the treatment of Myalgic Encephalomylitis/Chronic Fatigue Syndrome.

The Complaint alleges that throughout the Class Period, the Company made a host of materially false and misleading statements regarding the safety and efficacy of Ampligen, and touted purportedly positive results from Ampligen's clinical trials. As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On December 18, 2012, the FDA published an FDA staff report concerning Ampligen's safety and efficacy. Specifically, the report concluded that the Company's studies were "ill-defined and invalid" with signals of efficacy that were inconsistent between clinical trials, and based on the limited quality of the data, "it is difficult to draw conclusions regarding potential safety signals," but the "review identified nine potential safety concerns associated with Ampligen."

On this news, Hemispherx shares declined $0.276 per share or nearly 43%, to close at $0.368 per share on December 18, 2012.

If you are a member of the class, you may, no later than February 22, 2013, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information about the case or to participate online, please visit: www.rmclasslaw.com/cases/heb or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or by e-mail at [email protected] For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

    CONTACT: Ryan & Maniskas, LLP
             Richard A. Maniskas, Esquire
             995 Old Eagle School Rd., Suite 311
             Wayne, PA 19087
             [email protected]

SOURCE Ryan & Maniskas, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22 HEMISPHERX BIOPHARMA INC : Change in Directors or Principal Officers (form 8-K)
06/01 HEMISPHERX BIOPHARMA, INC. (NYSEMKT : HEB) Files An 8-K Entry into a Material De..
06/01 HEMISPHERX BIOPHARMA INC : Entry into a Material Definitive Agreement, Unregiste..
06/01 HEMISPHERX BIOPHARMA : Enhances Ampligen Manufacturing and Scientific Capabiliti..
06/01 HEMISPHERX BIOPHARMA : Repurposes Ampligen in Immuno-Oncology
05/31 HEMISPHERX BIOPHARMA : Repurposes Ampligen in Immuno-Oncology
05/31 HEMISPHERX BIOPHARMA : Enhances Ampligen Manufacturing and Scientific Capabiliti..
05/15 HEMISPHERX BIOPHARMA INC : Management's Discussion and Analysis of Financial Con..
05/15 Hemispherx Biopharma Announces Financial Results for the Three Months Ended M..
05/08 HEMISPHERX BIOPHARMA, INC. (NYSEMKT : HEB) Files An 8-K Entry into a Material De..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Hemispherx Bio's Ampligen OK'd in Argentina; shares up 46% premarket
2016 Hemispherx Biopharma reports Q2 results
2016 FDA OKs new cell culture-derived flu vaccine
2016 Hemispherx's (HEB) CEO Tom Equels on Q1 2016 Results - Earnings Call Transcri..